VIM and systemic sclerosis: The vimentin immunization model of systemic sclerosis exhibited accelerated skin and lung fibrosis compared to the bleomycin (BLM)-induced model, along with increased activation of Th2 and Th17 cells and enhanced autoantibody production against vimentin.